217 related articles for article (PubMed ID: 37713871)
21. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
22. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
23. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
24. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
25. [IgG Fc binding protein (FCGBP) as a prognostic marker of low-grade glioma and its correlation analysis with immune infiltration].
Liu Q; Zhang J; Zhang F; Zhang W; Gong L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Aug; 39(8):686-692. PubMed ID: 37515334
[TBL] [Abstract][Full Text] [Related]
26. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
27. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response.
Tian R; Li Y; Shu M
Front Immunol; 2021; 12():797450. PubMed ID: 35069579
[TBL] [Abstract][Full Text] [Related]
28. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
29. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
Xu S; Wang Z; Ye J; Mei S; Zhang J
Front Oncol; 2021; 11():729103. PubMed ID: 34568059
[TBL] [Abstract][Full Text] [Related]
30. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
31. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
32. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
33. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
34. SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma.
Cao K; Jiang X; Wang B; Ni Z; Chen Y
Front Neurol; 2022; 13():905561. PubMed ID: 35756918
[TBL] [Abstract][Full Text] [Related]
35. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
36. EPHB2 as a key mediator of glioma progression: Insights from microenvironmental receptor ligand-related prognostic gene signature.
Tan L; Zhou J; Nie Z; Li D; Wang B
Genomics; 2024 May; 116(3):110799. PubMed ID: 38286348
[TBL] [Abstract][Full Text] [Related]
37. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
38. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
39. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
40. Mining immune-related genes with prognostic value in the tumor microenvironment of breast invasive ductal carcinoma.
He Q; Xue S; Wa Q; He M; Feng S; Chen Z; Chen W; Luo X
Medicine (Baltimore); 2021 Apr; 100(17):e25715. PubMed ID: 33907159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
